CriticalAntianginal – late sodium current inhibitor×Non-selective beta blocker with class III antiarrhythmic activity
Updated · Methodology
Mechanism
Ranolazine blocks the IKr potassium current and prolongs the heart-rate-corrected QT interval (QTc) in a concentration-dependent way. At doses of 500–1000 mg twice daily, the increase is about 2–7 ms (ranolazine summary of product characteristics, SmPC, European Medicines Agency, EMA). The ranolazine SmPC names sotalol as a class III antiarrhythmic (EMA). Sotalol itself prolongs the QT interval and can cause torsade de pointes, and the slow heart rate it produces raises this risk further (sotalol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). According to the ranolazine SmPC, combining it with other QTc-prolonging drugs could in theory cause a pharmacodynamic interaction and increase the risk of ventricular arrhythmias (EMA). Sotalol undergoes no metabolism, and the kidneys excrete 80–90% of the dose unchanged (sotalol SmPC, AEMPS). The documents describe no interaction of this pair through liver enzymes.
Symptoms
QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). Torsade de pointes with sotalol usually starts after treatment begins or after a dose increase, but it can also occur later. It may stop on its own or cause fainting, and in rare cases it progresses to ventricular fibrillation (sotalol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The risk is higher with a history of QT over 450 ms, a heart rate below 60 per minute, low potassium and magnesium, high sotalol levels from overdose or kidney failure, other QT-prolonging drugs, and apparently in women (sotalol SmPC, AEMPS). Ranolazine itself commonly causes dizziness, nausea and constipation, and uncommonly fainting and QT prolongation on the ECG (ranolazine SmPC, European Medicines Agency, EMA).
Management
The combination is contraindicated. The European ranolazine summary of product characteristics (SmPC) contraindicates ranolazine with class Ia and class III antiarrhythmics other than amiodarone and names sotalol (ranolazine SmPC, European Medicines Agency, EMA). The Spanish sotalol SmPC lists ranolazine among combinations it does not recommend and advises extreme caution when sotalol is given with QT-prolonging drugs (sotalol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US sotalol label advises avoiding such drugs (sotalol label, US Food and Drug Administration, FDA). The US ranolazine label has no contraindication and only notes little experience with other QT-prolonging drugs (ranolazine FDA label); the European SmPC is stricter. Use ranolazine with caution in congenital or familial long QT syndrome and known acquired QT prolongation (ranolazine SmPC, EMA). Sotalol is contraindicated in congenital or acquired long QT syndrome and torsade de pointes. Do not prescribe it until low potassium or magnesium has been corrected (sotalol SmPC, AEMPS). Start sotalol and change its dose with electrocardiogram (ECG) monitoring of the heart-rate-corrected QT interval (QTc), after assessing kidney function, electrolytes and concomitant medicines (sotalol SmPC, AEMPS). If QT or QRS lengthens by 25% or more, PQ by 50% or more, or QTc exceeds 480 ms, reassess benefit and risk and seriously consider a lower dose or stopping sotalol (sotalol SmPC, AEMPS). In angina, do not stop sotalol abruptly; reduce the dose gradually over one to two weeks (sotalol SmPC, AEMPS). The documents give no interval between stopping one drug and starting the other.
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Ranolazine extended-release tablets (Zydus Lifesciences) – prescribing information (2026)– FDA label, Zydus Lifesciences, DailyMed setid d74f3dea-7357-4e9a-be9a-2f498a44108a, version 5, 09/2026, sections 2.2, 4, 5.1, 7.1 and 7.2
- FDA: Betapace / Betapace AF (sotalol hydrochloride) tablets – prescribing information (2024)– FDA label, Legacy Pharma USA, DailyMed setid a6a7702f-36c9-45db-b640-453dc324baee, version 2, 12/2024, sections 4, 5.1 and 7.1
- EMA: Ficha técnica: Ranolazina (EU/1/08/462), sección 4.3 (2026)– EMA SmPC vía AEMPS CIMA, nº 08462001 (EU/1/08/462), secciones 4.3, 4.5 y 4.9, consultado 10/2026
- EMA: Ficha técnica: Ranolazina, Ranexa (EU/1/08/462), sección 4.4 (2026)– EMA, Ranexa 375 mg comprimidos de liberación prolongada (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 08462001, consultada 10/2026, sin fecha de revisión en CIMA, secciones 4.1, 4.4 y 4.5
- AEMPS: Ficha técnica: Sotalol, Sotapor 80 mg (nº registro 62001), sección 4.5 (2022)– AEMPS, CIMA, nº registro 62001 (Sotapor 80 mg comprimidos, Cheplapharm), revisión 11/2022 (texto revisado 09/2022), secciones 4.3, 4.4, 4.5 y 5.2